Literature DB >> 34393011

Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III.

Angela M Haeny1, Oladunni Oluwoye2, Rick Cruz3, Theddeus Iheanacho4, Asti B Jackson4, Sycarah Fisher5, Maria Crouch6, Stephanie O'Malley4.   

Abstract

BACKGROUND: Existing epidemiological data suggest differences across racial/ethnic groups in drug and alcohol treatment utilization and barriers to treatment and typically include only Black, Latine, and White adults. The objective of this study was to examine whether disparities remain for DSM-5 lifetime alcohol use disorder (AUD) and drug use disorder (DUD) treatment utilization and barriers across Black, American Indian/Alaska Native (AI/AN), Latine, Asian/Pacific Islander/Native Hawaiian (Asian/PI/NH), and White adults.
METHODS: The current study conducted secondary analyses on data from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC-III). Regression analyses, followed by pairwise comparisons, investigated differences across racial/ethnic groups.
RESULTS: Analyses indicated differences across racial/ethnic groups in AUD treatment utilization. White and AI/AN adults were more likely to utilize a health care professional than were Black adults. Asian/PI/NH and Latine adults were more likely to endorse language as a barrier to AUD treatment than were White adults. Black adults were more likely to use 12-step programs for DUD treatment utilization than were White and Latine adults, and Black and White adults were more likely to use outpatient programs than were Latine adults. Further, Black adults were more likely than Asian/PI/NH and Latine adults to use specialty DUD treatment. AI/AN, Asian/PI/NH, and White adults were more likely to endorse fear of what others would think as a barrier to DUD treatment relative to Black adults. AI/AN adults were more likely to endorse fear of being hospitalized relative to Black, Latine, and White adults. Asian/PI/NH and Latine adults were more likely to indicate that the hours were inconvenient relative to Black and White adults. White adults were more likely to endorse a family member objected relative to Black adults. AI/AN and White adults were more likely to endorse they stopped on their own relative to Black, Asian/PI/NH, and Latine adults. Further, AI/AN and White adults reported the greatest number of barriers to DUD treatment.
CONCLUSIONS: Differences remain across racial/ethnic group in drug and alcohol treatment utilization and barriers to treatment. Future research aimed at increasing treatment utilization across racial/ethnic groups should focus on social determinants of health.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcohol use disorder; Barriers to treatment; Drug use disorders; Racial disparities; Treatment utilization

Mesh:

Year:  2021        PMID: 34393011      PMCID: PMC9084614          DOI: 10.1016/j.jsat.2021.108569

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  41 in total

1.  Who goes to alcohol and drug treatment? Understanding utilization within the context of insurance.

Authors:  Constance Weisner; Helen Matzger; Tammy Tam; Laura Schmidt
Journal:  J Stud Alcohol       Date:  2002-11

2.  Drug use and service utilization among Hispanics in the United States.

Authors:  Michael A Mancini; Christopher P Salas-Wright; Michael G Vaughn
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-08-11       Impact factor: 4.328

3.  Ethnic disparities in clinical severity and services for alcohol problems: results from the National Alcohol Survey.

Authors:  Laura A Schmidt; Yu Ye; Thomas K Greenfield; Jason Bond
Journal:  Alcohol Clin Exp Res       Date:  2007-01       Impact factor: 3.455

4.  Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

Authors:  Bridget F Grant; Risë B Goldstein; Tulshi D Saha; S Patricia Chou; Jeesun Jung; Haitao Zhang; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin
Journal:  JAMA Psychiatry       Date:  2015-08       Impact factor: 21.596

5.  The efficacy of cognitive behavioral therapy for Chinese people: A meta-analysis.

Authors:  Ting Kin Ng; Daniel Fu Keung Wong
Journal:  Aust N Z J Psychiatry       Date:  2017-11-16       Impact factor: 5.744

6.  How to provide anti-racist mental health care.

Authors:  Jude Mary Cénat
Journal:  Lancet Psychiatry       Date:  2020-07-08       Impact factor: 27.083

Review 7.  Drinking, Alcohol Use Disorder, and Treatment Access and Utilization Among U.S. Racial/Ethnic Groups.

Authors:  Patrice A C Vaeth; Meme Wang-Schweig; Raul Caetano
Journal:  Alcohol Clin Exp Res       Date:  2016-12-26       Impact factor: 3.455

8.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): reliability of substance use and psychiatric disorder modules in a general population sample.

Authors:  Bridget F Grant; Rise B Goldstein; Sharon M Smith; Jeesun Jung; Haitao Zhang; Sanchen P Chou; Roger P Pickering; Wenjun J Ruan; Boji Huang; Tulshi D Saha; Christina Aivadyan; Eliana Greenstein; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2014-12-08       Impact factor: 4.492

9.  The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

Authors:  Bridget F Grant; Deborah A Dawson; Frederick S Stinson; S Patricia Chou; Mary C Dufour; Roger P Pickering
Journal:  Drug Alcohol Depend       Date:  2004-06-11       Impact factor: 4.492

10.  Culturally Adapted, Web-Based Cognitive Behavioral Therapy for Spanish-Speaking Individuals With Substance Use Disorders: A Randomized Clinical Trial.

Authors:  Manuel Paris; Michelle Silva; Luis Añez-Nava; Yudilyn Jaramillo; Brian D Kiluk; Melissa A Gordon; Charla Nich; Tami Frankforter; Kathleen Devore; Samuel A Ball; Kathleen M Carroll
Journal:  Am J Public Health       Date:  2018-09-25       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.